Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study
Titel:
Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study
Auteur:
Auliac, J. B. Fournier, C. Audigier Valette, C. Perol, M. Bizieux, A. Vinas, F. Decroisette Phan van Ho, C. Bota Ouchlif, S. Corre, R. Garff, G. Le Fournel, P. Baize, N. Lamy, R. Vergnenegre, A. Arpin, D. Marin, B. Chouaid, C. Gervais, R.